Agios Pharmaceuticals Inc (AGIO)
34.54
-0.04
(-0.12%)
USD |
NASDAQ |
May 03, 16:00
34.54
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Cash from Investing (Quarterly): 95.51M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 95.51M |
| September 30, 2023 | 39.34M |
| June 30, 2023 | 47.12M |
| March 31, 2023 | 57.60M |
| December 31, 2022 | 82.95M |
| September 30, 2022 | 104.07M |
| June 30, 2022 | 82.81M |
| March 31, 2022 | -26.57M |
| December 31, 2021 | -94.42M |
| September 30, 2021 | -232.73M |
| June 30, 2021 | -298.15M |
| March 31, 2021 | 1.874B |
| December 31, 2020 | 71.40M |
| September 30, 2020 | -126.24M |
| June 30, 2020 | 22.46M |
| March 31, 2020 | 108.14M |
| December 31, 2019 | -184.77M |
| September 30, 2019 | 80.38M |
| June 30, 2019 | 64.48M |
| March 31, 2019 | 131.35M |
| December 31, 2018 | -12.80M |
| September 30, 2018 | 2.771M |
| June 30, 2018 | -96.26M |
| March 31, 2018 | -167.53M |
| Date | Value |
|---|---|
| December 31, 2017 | 41.85M |
| September 30, 2017 | 66.42M |
| June 30, 2017 | -275.72M |
| March 31, 2017 | 109.55M |
| December 31, 2016 | -77.52M |
| September 30, 2016 | -62.74M |
| June 30, 2016 | 35.74M |
| March 31, 2016 | -14.83M |
| December 31, 2015 | 20.96M |
| September 30, 2015 | 30.16M |
| June 30, 2015 | 32.21M |
| March 31, 2015 | 44.99M |
| December 31, 2014 | -287.30M |
| September 30, 2014 | -15.10M |
| June 30, 2014 | -18.67M |
| March 31, 2014 | -12.26M |
| December 31, 2013 | -20.41M |
| September 30, 2013 | -80.72M |
| June 30, 2013 | 9.879M |
| March 31, 2013 | 4.036M |
| December 31, 2012 | 19.84M |
| September 30, 2012 | -1.722M |
| June 30, 2012 | -5.462M |
| March 31, 2012 | 10.39M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-298.15M
Minimum
Jun 2021
1.874B
Maximum
Mar 2021
93.02M
Average
57.60M
Median
Mar 2023
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -240.66M |
| Amgen Inc | -27.09B |
| Blueprint Medicines Corp | 78.77M |
| Corcept Therapeutics Inc | 17.10M |
| Ionis Pharmaceuticals Inc | -26.71M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -72.49M |
| Cash from Financing (Quarterly) | 0.847M |
| Free Cash Flow | -314.56M |
| Free Cash Flow Per Share (Quarterly) | -1.300 |
| Free Cash Flow to Equity (Quarterly) | -72.72M |
| Free Cash Flow Yield | -16.37% |